You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

2 Verastem insiders buy up stock

Two members of the board of biotechnology start-up Verastem Inc. have made large purchases of the Cambridge company’s common stock.

Lead director Henri A. Termeer, the retired chief executive of Genzyme Corp., bought 11,356 shares of Verastem at $9.35 apiece, documents filed with the Securities and Exchange Commission show.

Continue reading below

A separate document said director John K. Clarke, cofounder of the venture capital firm Cardinal Partners, bought 25,000 shares of Verastem at $9.21 a share, lifting his holdings to 2,305,959 shares.

Verastem’s chairman, Christoph Westphal, who will be stepping down as chief executive July 1, is the company’s largest shareholder, owning 17.5 percent of its stock as of April 25 — through personal holdings and as part of his partnership at a Boston venture firm, Longwood Fund. Westphal continues to add shares at regular intervals through a stock-buying plan.

Westphal will be replaced as Verastem’s chief executive by Robert Forrester, who currently serves as the company’s president and chief operating officer.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of